Multiplex Syndromic Panels Patents: Leaders & Filing Trends 2026
- Filing peaked in 2021 at 17 records, then fell to 2 by 2024 (-88%) — the pandemic-era surge in respiratory panel filings has not been repeated, and 2025-2026 figures are still filling in behind the ~18-month publication lag.
- A cartridge-processing lineage from a single assignee dominates the most-cited records with two related filings — one at 44 citations, one at 12 — both describing the same closed sample-preparation instrument.
- C12Q claims cover 74.5% of the 47 records in scope while healthcare informatics (G16H, 6.4%) and bioinformatics (G16B, 4.3%) remain thin, despite AI-assisted interpretation appearing in the single most-cited record.
Filing growth compares 2021 (17 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this patent set covers
Multiplex syndromic panels combine assays for multiple pathogens or targets into a single run, and the patent activity in this set clusters around three problems: how many targets a panel can carry without cross-reactivity, how the cartridge or instrument processes the sample, and how the result gets interpreted and reported. The search scope pulls together 47 published families filed between 2015 and mid-2026 that combine panel-design or respiratory-pathogen-panel language with claims touching target number, cross-reactivity, panel design, result interpretation, reimbursement, or turnaround time.
The filing curve tracks the diagnostics industry's own pandemic cycle: a build-up through the late 2010s, a peak in 2021, and a sharp pull-back by 2024. Because publication trails filing by roughly a year and a half, the most recent two years in the trend understate real activity rather than signal a genuine slowdown.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 47-record set: how filing activity has moved year over year, and which IPC subclasses carry the claims.
From a 2021 peak to a sharp pull-back
Filings ran from 7 in 2017 to a peak of 17 in 2021, then dropped to 2 by 2024 — an 88% fall over that three-year span. That decline should be read against the publication lag: 2025 and 2026 records are still arriving, so the true trajectory past 2024 is not yet visible in this data.
Claims concentrate in molecular assay classes
C12Q (enzyme/DNA measuring and testing) appears in 74.5% of the 47 records, with G01N (material analysis) at 36.2% and B01L (lab apparatus) at 21.3% close behind. Informatics-adjacent classes — G16H healthcare informatics and G16B bioinformatics — sit at 6.4% and 4.3% respectively, thin relative to how central AI-assisted interpretation is to the most-cited single record in the set.
Shares are the percentage of the 47 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Multiplex Syndromic Panels with Eureka
This page is one run against one query. Ask Eureka your own question about multiplex syndromic panels and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this set
Method and system for saliva testing for virus including COVID-19
The filing describes rapid isolation and characterization of nucleic acid, particularly RNA, from small-volume, self-collected saliva samples to determine the presence of infectious agent RNA, including viral and coronavirus RNA. It also covers strategies for pooling samples and RNA to detect the presence or absence of infectious agent RNA across pooled cohorts.Filed by The Rockefeller University; published 2023-09-07.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20210118559A1 | Artificial intelligence assisted precision medicine enhancements to standardized laboratory diagnostic testing | 87 |
| 2 | US20180095100A1 | Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system | 44 |
| 3 | WO2021202620A1 | Metabolomics approach combined with machine learning to recognize a medical condition | 14 |
| 4 | WO2018053501A1 | Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system | 12 |
| 5 | WO2021243080A1 | Magnetofluidic cartridges, devices and related methods of sample analysis | 4 |
| 6 | US20230201833A1 | Magnetofluidic cartridges, devices and related methods of sample analysis | 3 |
| 7 | US20210285039A1 | Looped primer and loop-de-loop method for detecting target nucleic acid | 3 |
| 8 | WO2023039553A2 | Looped primer with various internal modifications and loop-de-loop method for target detection | 2 |
| 9 | WO2022011215A1 | Method and system for saliva testing for virus including covid-19 | 2 |
| 10 | US11300578B2 | Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system | 2 |
Citation counts favour older records in any searched corpus — read them as a signal of influence on later filings, not as a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three patterns stand out once the trend and technology composition are read together.
The 2021 peak has not held
17 records published in 2021 fell to 2 by 2024, an 88% drop over three years. That decline lines up with the end of the acute pandemic testing surge rather than a structural retreat from the technology — the publication lag means 2025-2026 activity is not yet visible.
AI-assisted interpretation leads on influence
The most-cited record in the set, on AI-assisted precision-medicine enhancements to standardized lab testing, draws 87 citations — well ahead of the cartridge-processing filings that follow it. That gap suggests result-interpretation claims are drawing more downstream attention than the hardware they run on.
Assay chemistry claims dominate
Three in four records in scope touch C12Q enzyme/DNA measuring claims, while informatics classes (G16H, G16B) sit under 7% each. Software-driven interpretation layers are claimed far less densely than the underlying assay chemistry, even though the highest-cited record in the set is itself an informatics claim.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to multiplex syndromic panels, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Johns Hopkins University | The Regents of the University of California | 2 |
| The Rockefeller University | DARNELL ROBERT B | 1 |
Only two co-assignee pairs appear across the 47 records, one linking two university assignees and one linking a university with an individual inventor. Cross-institution collaboration is not yet a defining feature of this claim space.
Who holds the ranked claims
The assignee ranking returned by this dataset covers 12 companies, led by a filer with 20 records; fifth place holds 4 and tenth place holds 2. None of the ranked assignees show filings in the latest year, consistent with the post-2021 pull-back and the publication lag on recent activity.
A single assignee holds a clear lead
The top-ranked assignee holds 20 of the records in this 12-company ranking, well ahead of the field. That lead sits alongside the cartridge-processing instrument filings that anchor the most-cited table, suggesting platform-level claims rather than assay-chemistry claims are where this leader concentrates.
A drop-off after the leader
Fifth place in the ranking holds 4 records, and tenth place holds 2 — a steep fall from the leader's 20. That spread points to a long tail of assignees with small, defensive filing positions rather than a cluster of similarly-sized competitors.
Filing here is mostly solo
Only two co-assignee pairs appear across the ranked assignees, both involving university filers. Commercial assignees in this set do not show joint-filing patterns with each other in the data.
| Assignee | Recent year | YoY |
|---|---|---|
| UH OH Labs Inc | 0 | — |
| GenMark Diagnostics Inc | 0 | — |
| Johns Hopkins University | 0 | — |
| Gen-Probe Inc | 0 | — |
| Roche Molecular Systems Inc | 0 | — |
| The Rockefeller University | 0 | — |
| The Regents of the University of California | 0 | — |
| TEMPUS LABS INC | 0 | — |
Where to take this analysis
The dataset points to a field with concentrated assay-chemistry claims, a dominant cartridge-platform holder, and thin coverage in result-interpretation software. Three directions follow from that.
Map the cartridge-processing family in full
The two most-cited cartridge-processing filings share an assignee and a closed sample-preparation architecture — worth tracing the full family tree before designing new hardware around it.
Explore the citation networkTest the informatics white space
G16H and G16B classes sit under 7% of records despite the highest-cited filing being an AI-interpretation claim. A freedom-to-operate check on result-interpretation software claims specifically, rather than assay chemistry, may surface less-crowded ground.
Run a freedom-to-operate checkWatch for renewed filing once 2025-2026 data lands
The 2021-2024 decline reflects the end of acute pandemic testing demand, not necessarily a permanent retreat. Recheck the trend once the publication lag clears for the most recent two years.
Track filing trends in EurekaCommon questions on multiplex syndromic panel patents
The assignee ranking in this dataset covers 12 companies, with the leading filer holding 20 records against a fifth-place holder at 4 and a tenth-place holder at 2. That spread shows one dominant filer and a long tail of smaller positions rather than several similarly-sized competitors. The leader's position lines up with the cartridge-processing instrument filings that also top the most-cited records table, suggesting platform-level claims are where this filer has concentrated.
Filings rose to 17 records in 2021, the peak year in this dataset, before falling to 2 by 2024 — an 88% decline over that span. That timing coincides with the acute phase of pandemic-driven respiratory testing demand, when companies raced to file panel-design and cartridge claims. The subsequent drop reflects the end of that surge rather than a structural retreat, and because publication lags filing by roughly 18 months, the 2025-2026 figures in any dataset will still be incomplete.
C12Q, covering enzyme and DNA measuring and testing, appears in 74.5% of the 47 records in scope, making it by far the most heavily claimed area. G01N material analysis (36.2%) and B01L lab apparatus (21.3%) follow. Informatics-related classes — G16H healthcare informatics and G16B bioinformatics — sit at only 6.4% and 4.3% respectively, indicating assay chemistry and hardware are more densely claimed than the software layers used to interpret results.
Yes, based on the class-density gap in this dataset: AI-assisted and bioinformatics-driven result interpretation sits under 7% of records even though the single most-cited filing in the set is itself an AI-assisted interpretation claim. Reimbursement-linked turnaround-time claims and cross-reactivity suppression for high-target-count panels also show thinner coverage relative to core C12Q assay claims. These are areas where a well-drafted first claim may face less prior art than the crowded assay-chemistry space.
US20230279511A1, assigned to The Rockefeller University and published 2023-09-07, covers methods for isolating and characterizing RNA — particularly viral and coronavirus RNA — from small-volume, self-collected saliva samples, including strategies for pooling samples to detect infectious agent RNA across a cohort. Anyone building a saliva-based multiplex panel with sample-pooling logic should review its claims closely before finalizing a pooling workflow. It does not, on its own, cover cartridge hardware or non-saliva sample types, so panels built on other sample matrices sit outside its direct claim scope.
Research Multiplex Syndromic Panels in depth with Eureka
Go past this page: query the whole multiplex syndromic panels corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.